Overview
- Management raised 2026 adjusted EBITDA guidance to $120–$124 million and kept revenue guidance at $1.40–$1.42 billion.
- For 2025, organic revenue grew 13% with reported growth of 18%, adjusted EBITDA rose 27% to $115 million, and Q4 adjusted EBITDA increased 53% to $39.5 million with a 7.9% margin.
- Leaders said IRA-related pricing effects are expected to be offset in 2026, with an estimated revenue headwind of about $65 million in 2027.
- Operational tailwinds included serving more than 205,000 residents, fourth-quarter script volume up 14%, improved vaccine economics, over 100,000 clinical interventions, and $56 million in resident cost savings.
- Cash reached roughly $66 million after a near $60 million increase, three mid-year acquisitions and greenfield starts were funded from cash flow, and return on equity for the year was 27%.